EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Age of Antibiotic Resistance in MDR/XDR Clinical Pathogen of Pseudomonas aeruginosa

Ashish Kothari iD, Radhika Kherdekar, Vishal Mago iD, Madhur Uniyal, Garima Mamgain, Roop Bhushan Kalia, Sandeep Kumar, Neeraj Jain iD, Atul Pandey iD, Balram Ji Omar iD

Pharmaceuticals · 30.08.2023 · 16 (9) · 1230

DOI: 10.3390/ph16091230 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Pharmaceuticals, online erschienen am 30.08.2023. Verfasst von Ashish Kothari und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Microbiology, All India Institute of Medical Sciences, Rishikesh 249203, India. Die Arbeit wurde bisher 37-mal zitiert (Crossref) und nennt 224 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: SERB-DST core research, ICMR SRF/RA fellowship.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Antibiotic resistance in Pseudomonas aeruginosa remains one of the most challenging phenomena of everyday medical science. The universal spread of high-risk clones of multidrug-resistant/extensively drug-resistant (MDR/XDR) clinical P. aeruginosa has become a public health threat. The P. aeruginosa bacteria exhibits remarkable genome plasticity that utilizes highly acquired and intrinsic resistance mechanisms to counter most antibiotic challenges. In addition, the adaptive antibiotic resistance of P. aeruginosa, including biofilm-mediated resistance and the formation of multidrug-tolerant persisted cells, are accountable for recalcitrance and relapse of infections. We highlighted the AMR mechanism considering the most common pathogen P. aeruginosa, its clinical impact, epidemiology, and save our souls (SOS)-mediated resistance. We further discussed the current therapeutic options against MDR/XDR P. aeruginosa infections, and described those treatment options in clinical practice. Finally, other therapeutic strategies, such as bacteriophage-based therapy and antimicrobial peptides, were described with clinical relevance.

Schlagwörter

Stichwörter der Autor:innen

antibiotic stewardshipdeveloping new antimicrobialsdrug-resistantefflux pump systemspublic health concern

Autor:innen und Institutionen

  • Department of Microbiology, All India Institute of Medical Sciences, Rishikesh 249203, India.
  • Department of Dentistry, All India Institute of Medical Sciences, Rishikesh 249203, India.
  • Department of Burn and Plastic Surgery, All India Institute of Medical Sciences, Rishikesh 249203, India.
  • Department of Trauma Surgery, All India Institute of Medical Sciences, Rishikesh 249203, India.
  • Department of Biochemistry, All India Institute of Medical Sciences, Rishikesh 249203, India.
  • Department of Orthopaedics, All India Institute of Medical Sciences, Rishikesh 249203, India.

ORCID-Profile: Ashish Kothari, Vishal Mago, Neeraj Jain, Atul Pandey, Balram Ji Omar

Förderung

  • SERB-DST core research
  • ICMR SRF/RA fellowship

Zitieren

APA

Kothari, A., Kherdekar, R., Mago, V., Uniyal, M., Mamgain, G., Kalia, R. B., Kumar, S., Jain, N., Pandey, A., & Omar, B. J. (2023). Age of Antibiotic Resistance in MDR/XDR Clinical Pathogen of Pseudomonas aeruginosa. Pharmaceuticals, 16(9), 1230. https://doi.org/10.3390/ph16091230

Vancouver

Kothari A, Kherdekar R, Mago V, Uniyal M, Mamgain G, Kalia RB, et al. Age of Antibiotic Resistance in MDR/XDR Clinical Pathogen of Pseudomonas aeruginosa. Pharmaceuticals. 2023;16(9):1230. doi:10.3390/ph16091230

BibTeX
@article{Kothari2023,
  author = {Kothari, Ashish and Kherdekar, Radhika and Mago, Vishal and Uniyal, Madhur and Mamgain, Garima and Kalia, Roop Bhushan and Kumar, Sandeep and Jain, Neeraj and Pandey, Atul and Omar, Balram Ji},
  title = {Age of Antibiotic Resistance in MDR/XDR Clinical Pathogen of Pseudomonas aeruginosa},
  journal = {Pharmaceuticals},
  year = {2023},
  volume = {16},
  number = {9},
  pages = {1230},
  doi = {10.3390/ph16091230}
}
Kostenlos starten →